News
US Food and Drug Administration Commissioner Marty Makary said he’s “taking a hard look” at whether a gene therapy from ...
Drugmaker Sarepta Therapeutics says it won’t comply with a request from U.S. regulators to halt all shipments of its gene ...
1d
Axios on MSNFDA panel backs menopausal hormone therapyAn Food and Drug Administration expert panel on Thursday endorsed removing the "black box" warning on hormone treatments for ...
FDA Commissioner Marty Makary's vision for the agency risks the best of an agency that mostly has functioned well for the ...
18h
MedPage Today on MSNRemove Boxed Warning on Hormone Therapy for Menopause, FDA Panel SaysA panel selected by FDA Commissioner Marty Makary, MD, MPH, unanimously urged the agency to remove the boxed warning on ...
2h
NBC4 WCMH-TV on MSNSarepta Therapeutics lays off 500 employees amid FDA investigation, including 80 in ColumbusSarepta Therapeutics announced it is laying off nearly 500 employees this week, including 80 at its Easton location.
1d
MedPage Today on MSNA 'Culture Change' Is Needed in Academic Medicine, FDA Commissioner SaysThe culture of academic medicine needs to change, FDA Commissioner Marty Makary, MD, MPH, said at an event sponsored by The ...
1d
News Nation on MSNFDA chief: HRT warning among ‘greatest mistakes of modern medicine’( NewsNation) — The head of the U.S. Food and Drug Administration signaled Thursday that he supports changing or removing the ...
22h
Stocktwits on MSNFDA Is Reportedly ‘Taking A Hard Look’ To Evaluate Whether Sarepta’s Gene Therapy Elevidys Should Remain On The MarketUS Food and Drug Administration Commissioner Marty Makary said he’s “taking a hard look” at whether Sarepta Therapeutics’ gene therapy, Elevidys, should remain on the market, following recent patient ...
During a press conference on Monday, Food and Drug Administration Commissioner Marty Makary spoke about the agency's ...
The U.S. Food and Drug Administration is planning to ask Sarepta Therapeutics to voluntarily stop all shipments of its gene ...
It is unclear how the Trump administration will consider affordability when reviewing a drug, as prices are usually ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results